William Blair Reaffirms “Outperform” Rating for Verve Therapeutics (NASDAQ:VERV)
William Blair restated their outperform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note published on Friday morning,RTT News reports. Several other equities research analysts also recently commented on the stock. HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” […]
William Blair restated their outperform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note published on Friday morning,RTT News reports. Several other equities research analysts also recently commented on the stock. HC Wainwright lowered their price objective on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” […]
